Sign In
Buy RGEN
$149.78
+2.72 (+1.85%)
At Close: Aug 04, 2026
Repligen's Q1 Earnings & Revenues Beat Estimates, Stock Rises
12:50pm, Wednesday, 06'th May 2026
RGEN tops Q1 earnings and revenue estimates, sending shares higher as strong chromatography and analytics business aid growth. The company raises its 2026 EPS view.
Repligen Corporation (RGEN) Q1 2026 Earnings Call Transcript
02:41pm, Tuesday, 05'th May 2026
Repligen Corporation (RGEN) Q1 2026 Earnings Call Transcript
Repligen (RGEN) Q1 Earnings and Revenues Beat Estimates
10:15am, Tuesday, 05'th May 2026
Repligen (RGEN) came out with quarterly earnings of $0.48 per share, beating the Zacks Consensus Estimate of $0.38 per share. This compares to earnings of $0.39 per share a year ago.
Repligen Reports First Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance
07:00am, Tuesday, 05'th May 2026
WALTHAM, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fi
Guardant Health (GH) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
11:01am, Thursday, 30'th Apr 2026
Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alger Mid Cap Growth Fund Q1 2026 Portfolio Review
04:10am, Wednesday, 29'th Apr 2026
Class A shares of the Alger Mid Cap Growth Fund underperformed the Russell Midcap Growth Index during the first quarter of 2026. FTAI Aviation Ltd., Vertiv Holdings Co. and Comfort Systems USA, Inc.,
Analysts Estimate Repligen (RGEN) to Report a Decline in Earnings: What to Look Out for
11:06am, Tuesday, 28'th Apr 2026
Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Conestoga Capital SMid Cap Composite Q1 2026 Portfolio Holdings
03:29pm, Monday, 27'th Apr 2026
The Conestoga SMid Cap Composite returned -10.24% net-of-fees in the first quarter, lagging the Russell 2500 Growth Index's return of -3.52%. RBC's performance was driven by continued strength in aero
Repligen to Report First Quarter 2026 Financial Results
07:30am, Wednesday, 22'nd Apr 2026
Webcast and Conference Call to Be Held Tuesday, May 5, 2026, at 8:00 a.m. ET Webcast and Conference Call to Be Held Tuesday, May 5, 2026, at 8:00 a.m. ET
Repligen Opens European Training & Innovation Center in Breda, Expanding Global Customer Support Network
07:30am, Friday, 17'th Apr 2026
WALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the grand opening of its
Massachusetts Financial Services Co. MA Makes New $199.18 Million Investment in Repligen Corporation $RGEN
05:28am, Monday, 13'th Apr 2026
Massachusetts Financial Services Co. MA acquired a new position in Repligen Corporation (NASDAQ: RGEN) in the fourth quarter, according to the company in its most recent filing with the Securities and
Azzad Asset Management Inc. ADV Has $543,000 Position in Repligen Corporation $RGEN
03:40am, Thursday, 09'th Apr 2026
Azzad Asset Management Inc. ADV cut its stake in shares of Repligen Corporation (NASDAQ: RGEN) by 59.5% during the undefined quarter, according to its most recent 13F filing with the Securities and Ex
Repligen (RGEN) Down 13.5% Since Last Earnings Report: Can It Rebound?
12:32pm, Thursday, 26'th Mar 2026
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?
Repligen Corporation $RGEN Stock Position Raised by Congress Asset Management Co.
01:39pm, Tuesday, 24'th Mar 2026
Congress Asset Management Co. grew its position in shares of Repligen Corporation (NASDAQ: RGEN) by 241.4% in the undefined quarter, according to the company in its most recent filing with the Securit
Repligen Conference: CEO touts differentiated bioprocessing portfolio; CFO targets 30% EBITDA margin
02:03am, Monday, 23'rd Mar 2026
Repligen (NASDAQ: RGEN) executives outlined a strategy focused on portfolio breadth, innovation, and commercial execution during a recent discussion with Life Science Analyst Paul Knight. Chief Execut
